Christopher Sarchi net worth and biography

Christopher Sarchi Biography and Net Worth

Insider of Replimune Group

Chris Sarchi joined Replimune as Chief Commercial Officer in December of 2022. Chris brings over 30 years of experience in the pharmaceutical industry, with 28 years dedicated to the field on Oncology working at GSK, Roche/Genentech, Boehringer-Ingelheim, and most recently at Sanofi where he served as the General Manager and Head of Oncology in the US. He has been involved with 9 new product launches in oncology covering multiple tumor types, as well as supportive care products. Among these milestones, Chris led Libtayo’s launch as a new standard of care in CSCC, and was also involved with the launch of Erivedge in Basel Cell Carcinoma while at Genentech. Chris received a Bachelor of Science in Business Administration from the University of Maine.

What is Christopher Sarchi's net worth?: The estimated net worth of Christopher Sarchi is at least $725,100.72 as of May 16th, 2024. Sarchi owns 92,252 shares of Replimune Group stock worth more than $725,101 as of May 13th. This net worth evaluation does not reflect any other assets that Sarchi may own. Learn More about Christopher Sarchi's net worth.
How old is Christopher Sarchi?: Sarchi is currently 56 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Christopher Sarchi's age.
How do I contact Christopher Sarchi?: The corporate mailing address for Sarchi and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Christopher Sarchi's contact information.
Has Christopher Sarchi been buying or selling shares of Replimune Group?: Christopher Sarchi has not been actively trading shares of Replimune Group during the last ninety days. Most recently, Christopher Sarchi sold 2,218 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a transaction totalling $14,350.46. Following the completion of the sale, the insider now directly owns 92,252 shares of the company's stock, valued at $596,870.44. Learn More on Christopher Sarchi's trading history.
Who are Replimune Group's active insiders?: Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.
Are insiders buying or selling shares of Replimune Group?: During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.
Information on this page was last updated on 12/16/2024.

Christopher Sarchi Insider Trading History at Replimune Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2024	Sell	2,218	$6.47	$14,350.46	92,252

Christopher Sarchi Buying and Selling Activity at Replimune Group

Replimune Group Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $7.86

$7.67

$8.28

50 Day Range

MA: $9.27

$6.92

$12.11

2 Week Range

Now: $7.86

$4.92

$17.00

Volume

764,794 shs

Average Volume

895,234 shs

Market Capitalization

$605.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Christopher Sarchi Biography and Net Worth

What is Christopher Sarchi's net worth?

How old is Christopher Sarchi?

How do I contact Christopher Sarchi?

Has Christopher Sarchi been buying or selling shares of Replimune Group?

Who are Replimune Group's active insiders?

Are insiders buying or selling shares of Replimune Group?